ACET Stock Analysis: Buy, Sell, or Hold?
ACET - Adicet Bio, Inc. Common Stock
$8.06
-0.61 (-7.04%)
▼
5d:
+15.14%
30d:
+16.47%
90d:
+2.03%
BUY
MODERATE Confidence
Analysis Updated: Apr 21, 2026 12:00 AM ET
Earnings: May 05, 2026
12d
Smart Money Distribution
ACET is up 20.9% this week, but smart money is buying puts. Top strike: $5 2026-05-15 with 1 OI. Put ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When ACET Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ACET shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ACET shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ACET is currently trading at $8.06, which is considered extended relative to its 30-day fair value range of $6.43 to $7.66.
Technical Outlook: Technically, ACET is in a strong uptrend. Immediate support is located at $6.05, while resistance sits at $8.79. Short-term momentum is weak, with the stock down 7.0% recently.
Market Sentiment: ACET has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $53.00 (+557.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACET is in a strong uptrend. Immediate support is located at $6.05, while resistance sits at $8.79. Short-term momentum is weak, with the stock down 7.0% recently.
Market Sentiment: ACET has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $53.00 (+557.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$6.43 -
$7.66
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
62.5%
All Signals
- BEARISH: Price extended above range (+5.2% above fair value)
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.0%)
- BULLISH: Trading 557.6% below Wall St target ($53.00)
Fair Price Analysis
30-Day Fair Range
$6.43 -
$7.66
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$1.02
(12.7%)
Support & Resistance Levels
Support Level
$6.05
Resistance Level
$8.79
Current Trend
Strong Uptrend
Technical data as of
Apr 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.40
Wall Street Target
$53.00
(+557.6%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: April 22, 2026 4:06 AM ET
Data refreshes hourly during market hours. Next update: 5:06 AM
Data refreshes hourly during market hours. Next update: 5:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACET showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$93 | 64 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$98 | 57 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 62 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 60 BUY |
